NSE: GLAXO | BSE: 500660

Strong Performer, Getting Expensive

Download real time

3439.60 137.70 (4.17%)

High volume today

NSE 27 Jun, 2025 3:31 PM (IST)

58,268.9

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

13 Feb 2018

3439.60

4.17%

GlaxoSmithKline

Sell: GlaxoSmithKline Pharmaceut...

Target

Centrum Broking

We maintain Sell rating on GlaxoSmithKline Pharma (GSK) and revise our TP to Rs1,850 (earlier Rs1,525) based on 24x March'20E EPS of Rs77.1. GSK's Q3FY18 results were below our and consensus estimates. GSK revenue was flat, EBIDTA margin improved 1,270bps to 20.1% and net profit grew 156% YoY. GSK's major brands grew by high single digit to double digit during the quarter. That said, the company has a strong presence in the vaccines segment and is likely to derive growth from the same. Key risks to our assumptions include faster-thanexpected growth in the domestic market and higher growth of its flagship brands. We recommend a switch to other pharma companies, Abbott India or...

GlaxoSmithKline Pharmaceuticals Ltd. has gained 53.33% in the last 6 Months

GlaxoSmithKline Pharmaceuticals Ltd.

05 Feb 2018

3439.60

4.17%

GSK Pharma: Revenues below estimates, margins in line (Feb 05, 2018)

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Revenues for the quarter at Rs 7039 mn were below our estimates of Rs7760mn. The margins were in-line with our estimate and stood at 20% inQ3FY18 as against 7.4% in Q3FY17. Higher margins were mainly onaccount of better gross margins.

Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

20 Nov 2017

3439.60

4.17%

Result Updates

Sell: GlaxoSmithKline Pharmaceut...

Angel Broking

GlaxoSmithKline Pharmaceuticals (GSK) posted better than expected results on sales and OPM fronts for 2QFY2018. The revenues came in at `836cr v/s. `800r expected, registering a yoy growth of 4.6%, mainly on the back of GST implementation. On the OPM front, the EBDITA margins came in at 23.0% (v/s. 15.3% expected) as compared to 17.6% in ..

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

25 Oct 2017

3439.60

4.17%

GlaxoSmithKline

Sell: GlaxoSmithKline Pharmaceut...

Centrum Broking

We maintain our Sell rating on GlaxoSmithKline Pharma (GSK) and revise our TP to Rs1,525 (earlier Rs1,390) based on 24x March'19E EPS of Rs63.4. GSK's Q2FY18 results exceeded our and consensus estimates. GSK revenue grew by 5%, EBIDTA margin improved 540bps to 23.0% and net profit grew 27% YoY. GSK's pharma segment grew by 6.3% during the quarter. That said, the company has a strong presence in the vaccines segment and is likely to derive growth from the same. Key risks to our assumptions include faster-thanexpected growth in the domestic market and higher growth of its flagship brands. We recommend a switch to other pharma companies, Abbott India or...

GlaxoSmithKline Pharmaceuticals Ltd. has gained 53.33% in the last 6 Months

GlaxoSmithKline Pharmaceuticals Ltd.

25 Oct 2017

3439.60

4.17%

GSK Pharma: Revenue impacted by GST rollout; margins surprise positiv

Neutral: GlaxoSmithKline Pharmaceut...

Motilal Oswal

~32% YoY to INR1.3b (+3% v/s our est.), including INR52m of one-time income from the sale of properties. Significant recovery in inventory post GST: GLXO saw a huge improvement on the revenue front sequentially (up 43% QoQ), primarily due to a recovery in inventory to pre-GST level. Notably, GSK lost around two weeks of sales in 1QFY18. Although revenue increased YoY, it was impacted by 6% due to price deflation led by GST (but profit-level impact of GST was neutral). After adjusting for price deflation, margins stood at ~22%. With inventory levels...

GlaxoSmithKline Pharmaceuticals Ltd. has gained 32.23% in the last 1 Year

GlaxoSmithKline Pharmaceuticals Ltd.

03 Aug 2017

3439.60

4.17%

Result Updates

Neutral: GlaxoSmithKline Pharmaceut...

Angel Broking

GlaxoSmithKline Pharmaceuticals (GSK) posted lower than expected results on sales and OPM fronts for 1QFY2018. The revenues came in at `587cr v/s. `700cr expected, registering a yoy de-growth of 14.3%, mainly on the back of GST implementation. On the OPM front, the EBDITA margins came in at (0.1)% (v/s. 12.6% expected) as compared to 10.2..

Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr

GlaxoSmithKline Pharmaceuticals Ltd.

26 May 2017, 06:58PM

3439.60

4.17%

Glaxosmithkline Pharma Ltd Q4FY17 results comment

Results Update: GlaxoSmithKline Pharmaceut...

HDFC Securities

Revenue grew by 10.76% to Rs. 763.43 Cr in Q4FY17 when compared to the previous quarter.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 22.04% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

23 May 2017

3439.60

4.17%

Result Updates

Results Update: GlaxoSmithKline Pharmaceut...

Angel Broking

GlaxoSmithKline Pharmaceuticals (GSK) posted better than expected results on sales and OPM fronts for 4QFY2017. The revenues came in at `763cr v/s `690cr expected, registering a yoy growth of 10.9%. On the OPM front, the EBDITA margins came in at 15.2% (v/s 11.3% expected) as compared to 16.1% in 4QFY2016. The Adj. PAT for the quarter cam..

GlaxoSmithKline Pharmaceuticals Ltd. has gained 22.04% in the last 3 Months

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

120 Votes:

Buy 65.0%

Sell 21.67%

Hold 13.33%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf